Special Authorization

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Special Authorization"

Transcription

1 Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization? Your drug plan provides you with immediate access to about 10,000 prescription drugs. Certain other medications require Special Authorization before your prescription is eligible for coverage. Will I need to pay for my prescription myself? If the Special Authorization is approved, you will pay the lowest amount (copay) available in your plan for your prescription. If the Special Authorization is not approved, you may need to pay the full price of the prescription yourself. How do I apply for Special Authorization? Your doctor needs to provide a well-documented medical reason why you need to take the Special Authorization drug. Here s how you apply: 1. Complete the Special Authorization (SA) form; you can download the Special Authorization form from your plan administrator s website. Both you and your doctor will need to complete the form. Have your doctor or pharmacist call or fax the Special Authorization (SA) form to your plan administrator. 2. Once your request has been processed, you will be notified and you will also receive a letter in the mail. You will need to have the Special Authorization request approved to pay the lowest amount (co-pay) in your plan. 3. If your plan administrator needs more information, they may contact your doctor directly. 4. If the request is approved, have your prescription filled. If the special authorization request is denied, you and your doctor will be notified. Clinical Conditions in the Reformulary Special Authorization Drugs December

2 What happens to my Special Authorization request once it is sent to my plan administrator? Your request will be confidentially reviewed by a qualified medical reviewer, according to specific criteria. You will receive written notification of the decision, typically within seven to fourteen working days. In cases where a doctor requires an urgent response due to the medical condition, every effort will be made to respond promptly. If your request is approved, the approval will indicate the specified period of time. You will likely need to re-apply for Special Authorization after that specified time period. What if I am already taking a Special Authorization drug? If you are already taking a Special Authorization drug when your new drug plan launches, your drug will be grandfathered. This means that you may continue taking this drug at the lowest amount (co-pay). Please refer to Clinical Conditions in the Reformulary Grandfathered Drugs for more information. Any statement suggesting that you consider a particular drug, indicating that any drug is a preferred drug, or describing the effectiveness of a drug is not intended to be a substitute for your physician's advice, diagnosis or treatment, and should not be used to replace a health care professional, for diagnosis or for treatment. You should not act or rely on any Information provided in this document or in DrugFinder at without seeking the advice of a physician or health care professional. Clinical Conditions in the Reformulary Special Authorization Drugs December

3 ACTEMRA (tocilizumab) ADCIRCA (tadalafil) adefovir ADEMPAS (riociguat) AFINITOR, AFINITOR DISPERZ (everolimus) Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Hepatitis B ALDURAZYME (laronidase) Mucopolysaccharidosis I (MPS I) ALECENSARO (alectinib hydrochloride) APTIOM (eslicarbazepine) APTIVUS (tipranavir) ARANESP (darbepoetin alfa) AUBAGIO (teriflunomide) AVANDIA (rosiglitazone), AVANDAMET (rosiglitazone/metformin) AVONEX (interferon beta-1a) BANZEL (rufinamide) BENLYSTA (belimumab) BETASERON (interferon beta-1b) bosentan BOSULIF (bosutinib) BOTOX (onabotulinumtoxin A) Brenzys (etanercept) BRIVLERA (brivaracetam) butorphanol nasal spray Epilepsy HIV/AIDS Anemia Diabetes ++ Epilepsy Lupus Miscellaneous Conditions Ankylosing Spondylitis; Rheumatoid Arthritis Epilepsy Migraines CALCIJEX (calcitriol) Kidney Disease ++ Clinical Conditions in the Reformulary Special Authorization Drugs December

4 calcitriol (injectable) Kidney Disease ++ CAPRELSA (vandetanib) CARBAGLU (carglumic acid) CARIPUL (epoprostenol) CAYSTON (aztreonam) CELSENTRI (maraviroc) CEREZYME (imiglucerase) Chlorax (clidinium bromide + chlordiazepoxide hydrochloride) CIMZIA (certolizumab) cinacalcet CINQAIR (reslizumab) COPAXONE (glatiramer) COSENTYX (secukinumab) COTELLIC (cobimetinib) CYSTADANE (betaine) DAKLINZA (daclatasvir) DAXAS (roflumilast) deferasirox DIACOMIT (stiripentol) DIFICID (fidaxomicin) DUODOPA (carbidopa + levodopa) EGRIFTA (tesamorelin) ELAPRASE (idursulfase) Hyperammonaemia HIV/AIDS Gaucher Disease Gastrointestinal (GI) Disorders ++ Rheumatoid Arthritis (RA); Psoriatic Arthritis; Ankylosing Spondylitis Hyperparathyroidism; Hypercalcemia Asthma, COPD Ankylosing Spondylitis; Psoriasis; Psoriatic Arthritis Homocystinuria Asthma, COPD Chronic Iron Overload Epilepsy Antibiotics, Antifungals, Antivirals Parkinson s Disease HIV/AIDS Mucopolysaccharidosis II (MPS II) Clinical Conditions in the Reformulary Special Authorization Drugs December

5 ELELYSO (taliglucerase alfa) ENBREL (etanercept) ENTOCORT (budesonide) ENTRESTO (valsartan + sacubitril) ENTYVIO (vedolizumab) EPCLUSA (sofosbuvir + velpatasvir) EPREX (epoetin alfa) ERIVEDGE (vismodegib) erlotinib ESBRIET (pirfenidone) EXJADE (deferasirox) EXTAVIA (interferon beta-1b) EYLEA (aflibercept) FABRAZYME (agalsidase beta) FAMPYRA (fampridine) FERRIPROX (deferiprone) FIRAZYR (icatibant) FLOLAN (epoprostenol) FLUDARA (fludarabine) FORTEO (teriparatide) FOSRENOL (lanthanum carbonate hydrate) FUZEON (enfuvirtide) FYCOMPA (perampanel) GALEXOS (simeprevir) Gaucher Disease Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis Inflammatory Bowel Disease (IBD) Heart and Blood Pressure Conditions Inflammatory Bowel Disease (IBD) Anemia Idiopathic Pulmonary Fibrosis Chronic Iron Overload Other Eye Conditions Fabry Disease Iron Overload Hereditary Antioedema (HAE) Osteoporosis Hyperkalemia; Hyperphosphatemia HIV/AIDS Epilepsy Clinical Conditions in the Reformulary Special Authorization Drugs December

6 gefinitib GENOTROPIN (somatropin) GILENYA (fingolimod) GIOTRIF (afatinib) GLEEVEC (imatinib) Grastofil (filgrastim) HARVONI (ledipasvir + sofosbuvir) HEMANGIOL (propranolol hydrochloride) HEPSERA (adefovir) HOLKIRA PAK (ritonavir + paritaprevir + ombitasvir + dasabuvir) HUMATROPE (somatropin) HUMIRA (adalimumab) IBRANCE (palbociclib) ICLUSIG (ponatinib) ILARIS (canakinumab) imatinib IMBRUVICA (ibrutinib) Growth Hormone Deficiency -related Conditions Miscellaneous Conditions Hepatitis B Growth Hormone Deficiency Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Inflammatory Bowel Disease (IBD); Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis; Hidradenitis Suppurativa; Uveitis Juvenile Idiopathic Arthritis (JIA); Cryopyrin- Associated Periodic Syndrome (CAPS); Familial Mediterranean Fever (FMF); Hyperimmunoglobulin D syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD); Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) IMUNOVIR (inosine) Antibiotics, Antifungals, Antivirals ++ INCIVEK (telaprevir) Clinical Conditions in the Reformulary Special Authorization Drugs December

7 Inflectra (infliximab) INLYTA (axitinib) INVEGA TRINZA (paliperidone palmitate) IRESSA (gefitinib) JADENU (deferasirox) JAKAVI (ruxolitinib) JETREA (ocriplasmin) JINARC (tolvaptan) JUXTAPID (lomitapide) KALYDECO (ivacaftor) KEVZARA (sarilumab) KINERET (anakinra) KUVAN (sapropterin) LANCORA (ivabradine) LEMTRADA (alemtuzumab) LENVIMA (lenvatinib mesylate) LIBRAX (clidinium bromide + chlordiazepoxide hydrochloride) linezolid LUCENTIS (ranibizumab) MACUGEN (pegaptanib) MEKINIST (trametinib) METOJECT, METOJECT SUBCUTANEOUS (methotrexate) MODERIBA (ribavirin) Rheumatoid Arthritis; Psoriasis ; Psoriatic Arthritis; Ankylosing Spondylitis; Inflammatory Bowel Disease (IBD) Schizophrenia Chronic Iron Overload Other Eye Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD) Homozygous familial hypercholesterolemia (HoFH) Rheumatoid Arthritis Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Phenylketonuria Heart and Blood Pressure Disorders Gastrointestinal (GI) Disorders ++ Antibiotics, Antifungals, Antivirals Other Eye Conditions Other Eye Conditions Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Clinical Conditions in the Reformulary Special Authorization Drugs December

8 MULTAQ (dronedarone) Heart and Blood Pressure Conditions ++ MYOZYME (alglucosidase) NAGLAZYME (galsulfase) NEULASTA (pegfilgrastim) NEUPOGEN (filgrastim) NEUPRO (rotigotine) NEXAVAR (sorafenib) nitisinone NORDITROPIN NORDIFLEX (somatropin) NPLATE (romiplostim) NUCALA (mepolizumab) NUTROPIN AQ (somatropin) OFEV (nintedanib esilate) Omnitrope (somatropin) OPSUMIT (macitentan) ORENCIA (abatacept) ORFADIN (nitisinone) ORKAMBI (ivacaftor + lumacaftor) OTEZLA (apremilast) OZURDEX (dexamethasone) PHEBURANE (sodium phenylbutyrate) PLEGRIDY (peginterferon beta-1a) POMALYST (pomalidomide) POSANOL (posaconazole) Pompe's Disease Mucopolysaccharidosis VI (MPS VI, Maroteaux- Lamy syndrome) -related Conditions -related Conditions Parkinson s Disease Hereditary Tyrosinemia type 1 (HT-1) Growth Hormone Deficiency Refractory chronic immune thrombocytopenia purpura (ITP) Asthma, COPD Growth Hormone Deficiency Idiopathic Pulmonary Fibrosis (IPF) Growth Hormone Deficiency Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Hereditary Tyrosinemia type 1 (HT-1) Psoriasis; Psoriatic Arthritis Eye/Ear Inflammation Urea Cycle Disorders Antibiotics, Antifungals, Antivirals Clinical Conditions in the Reformulary Special Authorization Drugs December

9 PRALUENT (alirocumab) PROLASTIN-C (alpha 1-proteinase inhibitor) PULMOZYME (dornase alfa) QUINSAIR (levofloxacin) RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide) RAVICTI (sodium phenylbutyrate) REBIF (interferon beta-1a) REMICADE (infliximab) REMODULIN (treprostinil) RENAGEL (sevelamer hydrochloride) RENVELA (sevelamer carbonate) REPATHA (evolocumab) RESTASIS (ciclosporin) RETISERT (fluocinolone) REVATIO (sildenafil) REVESTIVE (teduglutide) REVLIMID (lenalidomide) REVOLADE (eltrombopag) RILUTEK (riluzole) riluzole RITUXAN (rituximab) SAIZEN (somatropin) High Cholesterol Congenital Alpha 1-Antitrypsin Deficiency Heart and Blood Pressure Conditions ++ Urea Cycle Disorders Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Inflammatory Bowel Disease (IBD); Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis Hyperkalemia; Hyperphosphatemia Hyperkalemia; Hyperphosphatemia High Cholesterol Dry Eye Other Eye Conditions Functional Bowel Disorders ; Refractory chronic immune thrombocytopenia purpura (ITP) Amyotropic Lateral Sclerosis (ALS) Amyotropic Lateral Sclerosis (ALS) Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Growth Hormone Deficiency Clinical Conditions in the Reformulary Special Authorization Drugs December

10 SAMSCA (tolvaptan) SAPHRIS (asenapine) SATIVEX (cannabidiol + delta-9- tetrahydrocannabinol) SEBIVO (telbivudine) SENSIPAR (cinacalcet) SIGNIFOR (pasireotide) SIGNIFOR LAR (pasireotide) sildenafil (20 mg) SIMPONI (golimumab) SIMPONI I.V. (golimumab) SOLIRIS (eculizumab) SOMAVERT (pegvisomant) SOVALDI (sofosbuvir) SPRYCEL (dasatinib) STELARA (ustekinumab) STIVARGA (regorafenib) STRENSIQ (asfotase alfa) SUNVEPRA (asunaprevir) SUTENT (sunitinib) tadalafil TAFINLAR (dabrafenib) TAGRISSO (osimertinib) TALTZ (ixekizumab) Hyponatremia Bipolar Disorder Pain Hepatitis B Hyperparathyroidism; Hypercalcemia Cushing's Disease Acromegaly Rheumatoid Arthritis; Psoriatic Arthritis; Inflammatory Bowel Disease (IBD); Ankylosing Spondylitis; Non-Radiographic Axial Spondyloarthritis Rheumatoid Arthritis Hemolytic uremic syndrome (HUS); Paroxysmal nocturnal hemoglobinuria (PNH) Acromegaly Psoriasis; Psoriatic Arthritis; Inflammatory Bowel Disease (IBD) Enzyme Replacement Therapy Psoriasis Clinical Conditions in the Reformulary Special Authorization Drugs December

11 TARCEVA (erlotinib) TASIGNA (nilotinib) TECFIDERA (dimethyl) TECHNIVIE (ritonavir + paritaprevir + ombitasvir) TEMODAL (temozolomide) temozolomide THALOMID (thalidomide) TOBI, TOBI PODHALER (tobramycin) tobramycin (Inhalation Solution) TRACLEER (bosentan) TYKERB (lapatinib) TYSABRI (natalizumab) ULORIC (febuxostat) UPTRAVI (selexipag) VFEND (voriconazole) VICTRELIS (boceprevir) VICTRELIS TRIPLE (boceprevir + peginterferon Alfa- 2B + ribavirin) VIMIZIM (elosulfase alfa) VISUDYNE (verteporfin) VOLIBRIS (ambrisentan) voriconazole (injectable) VOTRIENT (pazopanib) VPRIV (velaglucerase alfa) XALKORI (crizotinib) XELJANZ (tofacitinib) Gout Antibiotics, Antifungals, Antivirals Mucopolysaccharidosis IVA (MPS IVA) Other Eye Conditions Antibiotics, Antifungals, Antivirals Gaucher Disease Rheumatoid Arthritis Clinical Conditions in the Reformulary Special Authorization Drugs December

12 XEOMIN (incobotulinumtoxin A) XIAFLEX (collagenase clostridium histolyticum) XOLAIR (omalizumab) XTANDI (enzalutamide) ZAVESCA (miglustat) ZAXINE (rifaximin) ZELBORAF (vemurafenib) ZEPATIER (elbasvir + grazoprevir) ZINBRYTA (daclizumab beta) ZOLINZA (vorinostat) ZYDELIG (idelalisib) ZYKADIA (ceritinib) ZYTIGA (abiraterone acetate) ZYVOXAM (linezolid) Miscellaneous Conditions Dupuytren's contracture Asthma, COPD; Chronic Idiopathic Urticaria (CIU) Gaucher Disease; Niemann-Pick Disease Type C Hepatic Encephalopathy Antibiotics, Antifungals, Antivirals BRAND drugs are capitalized. Generic drugs are in italics. Symbol denotes grandfathered drugs. Please refer to Clinical Conditions in the Reformulary Grandfathered Drugs for more information ++ Only plan members already taking these drugs may continue to receive coverage for these drugs. Special Authorization will not be given to plan members with a new prescription due to clinical concerns. Clinical Conditions in the Reformulary Special Authorization Drugs December

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017 Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018 Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Pharmacy Services Request Types

Pharmacy Services Request Types FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

BCN Advantage SM requirements for drugs covered under the medical benefit

BCN Advantage SM requirements for drugs covered under the medical benefit J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: POLICY NUMBER: PHARMACY-63 EFFECTIVE DATE: 12/04 LAST REVIEW DATE: 1/29/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered

More information

Original Policy Date

Original Policy Date MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index

More information

Drug Effectiveness Review Project Summary Report Biologics (Targeted Immune Modulators)

Drug Effectiveness Review Project Summary Report Biologics (Targeted Immune Modulators) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

DRUG DISEASE APPROVAL GUIDELINES

DRUG DISEASE APPROVAL GUIDELINES Special Authorization Drugs and Approval Guidelines (Special authorization drugs may vary depending on plan) DRUG DISEASE APPROVAL GUIDELINES ACTEMRA IV (Tocilizumab) - Rheumatoid Arthritis - Systemic

More information

Quarterly Report on Completed Drug Submission Reviews

Quarterly Report on Completed Drug Submission Reviews Quarterly Report on Completed Drug Submission Reviews Overview Last updated October 18, 2017 The Quarterly Report on Completed Drug Submission Reviews report is divided into three reports for each year

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Medication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013

Medication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January

More information

Specialty Pipeline Update

Specialty Pipeline Update Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination

More information

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength Prior Authorization Form GEHA FEDERAL - STANDARD OPTION Autoimmune Conditions (FA-PA) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Biologic Immunomodulators Therapy Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Biologic Immunomodulators Therapy (Pharmacy Benefit Only) Prime Therapeutics

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK

More information

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses Actemra ACTEMRA INTRAVENOUS All medically accepted indications not otherwise excluded plus patients already started on tocilizumab for a covered use. Castleman's disease. Still's disease. Concurrent use

More information

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation

More information

Specialty Pipeline Update

Specialty Pipeline Update Specialty Pipeline Update D Drug Insights > December 2016 New drug information Rubraca (rucaparib): The U.S. Food and Drug Administration (FDA) granted accelerated approval to Clovis Oncology, Inc. s Rubraca

More information

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria

Buckeye Health Plan (MMP) 2016 Prior Authorization Criteria Buckeye Health Plan (MMP) 2016 Prior Authorization Instructions: 1. With this file, at the top, click Edit, then click Find. 2. In the Find box type the name of the medication you want to find. 3. Click

More information

Infusible Biologics Medical Policy Prior Authorization Program Summary

Infusible Biologics Medical Policy Prior Authorization Program Summary Infusible Biologics Medical Policy Prior Authorization Program Summary Precertification/Prior Authorization may be required under certain plans. Please verify each member s benefits. OBJECTIVE The intent

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association H.P. Acthar Gel (repository corticotropin) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: H.P. Acthar Gel (repository corticotropin) Prime Therapeutics

More information

Drug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions

Drug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Ally Rx D-SNP Current as of r 1, 2017

Ally Rx D-SNP Current as of r 1, 2017 Ally Rx D-SNP Current as of r 1, 2017 AMPYRA AMPYRA PA Moderate to severe renal impairment (CrCL less than or equal to 50ml/min), patient not able to walk 25 feet in 8-45 seconds. Documentation of diagnosis,

More information

Contents Please refer to Medical Policy I-31, Tocilizumab (Actemra) for additional information.

Contents Please refer to Medical Policy I-31, Tocilizumab (Actemra) for additional information. In This Issue January 2018 Coverage Criteria Revised for Alpha1-Proteinase Inhibitor Infusions... 2 Coverage Criteria Revised for Eculizumab (Soliris)... 3 Coverage Criteria Revised for Chimeric Antigen

More information

Drug Class Update: Biologics for Autoimmune Conditions

Drug Class Update: Biologics for Autoimmune Conditions Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses

Actemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses Actemra ACTEMRA INTRAVENOUS All medically accepted indications not otherwise excluded plus patients already started on tocilizumab for a covered use. Castleman's disease. Still's disease. Concurrent use

More information

Clinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Biologic DMARDs Reference Number: CP.CPA.194 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.194 Effective Date: 01.01.18 Last Review Date: 12.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Managing high-cost innovative medicines in Asia: what are the latest trends and real world practice? ISPOR Symposium September 5, 2016.

Managing high-cost innovative medicines in Asia: what are the latest trends and real world practice? ISPOR Symposium September 5, 2016. Managing high-cost innovative medicines in Asia: what are the latest trends and real world practice? ISPOR Symposium September 5, 2016 Agenda Introduction of panel members and moderator Australia China

More information

2016 MDwise HIP Medical Services that Require Prior Authorization

2016 MDwise HIP Medical Services that Require Prior Authorization 2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

J-Code Trade Name Drug Name Required Medical Information

J-Code Trade Name Drug Name Required Medical Information FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade

More information

2017 PRIOR AUTHORIZATION CRITERIA

2017 PRIOR AUTHORIZATION CRITERIA 2017 PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) UCare requires your physician to get prior authorization for certain

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January

More information

MEDICATION GUIDE HUMIRA

MEDICATION GUIDE HUMIRA MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This

More information

AAT DEFICIENCY. Products Affected Aralast Np INJ 1000MG, 500MG Glassia. Prior Authorization Criteria Health Alliance Plan_2016_HAPFB Updated: 10/2016

AAT DEFICIENCY. Products Affected Aralast Np INJ 1000MG, 500MG Glassia. Prior Authorization Criteria Health Alliance Plan_2016_HAPFB Updated: 10/2016 Prior Authorization Health Alliance Plan_2016_HAPFB Updated: 10/2016 AAT DEFICIENCY Products Affected Aralast Np INJ 1000MG, 500MG Glassia Prolastin-c Zemaira Covered Uses All FDA-approved indications

More information

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

More information

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations

More information

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,

More information

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Faculty Disclosures Dr. Holle has provided content expertise on patient education materials for Innocrin Pharmaceuticals

More information

Hepatitis C Medications Prior Authorization Criteria

Hepatitis C Medications Prior Authorization Criteria Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;

More information

Injections Requiring Prior Authorization

Injections Requiring Prior Authorization At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information

ORENCIA (oh-ren-see-ah) (abatacept)

ORENCIA (oh-ren-see-ah) (abatacept) 17.7 FDA-Approved Patient Labeling PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Read this Patient Information before you start receiving ORENCIA and each time before you are scheduled to receive

More information

REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Sarilumab in the 10MM Rheumatoid Arthritis (RA)

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary July 1, 2017 Bulletin #166 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: adapalene/benzoyl peroxide, topical

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. DIRECT ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS (HCV): DAKLINZA (daclatasvir) oral tablet EPCLUSA (velpatasvir, sofosbuvir) oral tablet HARVONI (ledipasvir, sofosbuvir) oral tablet MAVYRET (glecaprevir,

More information

Texas Prior Authorization Program Clinical Criteria

Texas Prior Authorization Program Clinical Criteria Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Aldurazyme Adagen Carbaglu Ceprotin Elaprase Fabrazyme Lumizyme Naglazyme Orfandin Ravicti Vimizim Note: Click the hyperlink to navigate

More information

(tofacitinib) are met.

(tofacitinib) are met. Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically

More information

New chemical Entity Registered ( )

New chemical Entity Registered ( ) N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Drug Store Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib

More information

Medications Guide June 2017

Medications Guide June 2017 s Guide June 2017 Arthritis Consumer Experts (ACE) produces its annual JointHealth Medications Guide to enable members/patients-at-large to have a meaningful conversation with their rheumatologist and

More information

OrphaNews Europe: How are orphan medicinal products categorised in Turkey?

OrphaNews Europe: How are orphan medicinal products categorised in Turkey? Spotlight on...medicinal products for rare diseases in Turkey Interview In November 2008, Turkish pharmacist Pelin Kilic joined the team of Orphanet France in order to pursue her PhD studies in gene technology,

More information

2017 Prior Authorization (PA) Criteria

2017 Prior Authorization (PA) Criteria 2017 Prior Authorization (PA) Certain drugs require prior authorization from GuildNet Gold Plus FIDA Plan Medicare Plans. This means that your doctor must contact us to get approval before prescribing

More information

New chemical Entity Registered ( )

New chemical Entity Registered ( ) N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina

More information

SelectHealth Advantage 2015 Prior Authorization Criteria

SelectHealth Advantage 2015 Prior Authorization Criteria ACROMEGALY Somatuline Depot, Somavert 1. Pt has had surgical resection of the pituitary gland OR is not a candidate for surgery/radiation therapy, 2. Patient has tried at least ONE of the following: a.

More information

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64 Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra

More information

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription

More information

2017 PRIOR AUTHORIZATION CRITERIA

2017 PRIOR AUTHORIZATION CRITERIA 2017 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare

More information

MEDICATION GUIDE. (tocilizumab)

MEDICATION GUIDE. (tocilizumab) MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place

More information

Health Newsflash A Quarterly Publication

Health Newsflash A Quarterly Publication The Drug Evaluation Committee (DEC) of Express Scripts Canada conducts monthly reviews of all new drugs receiving their Notice of Compliance from Health Canada, to ascertain their place in therapy and

More information

2017 Prior Authorization (PA) Criteria

2017 Prior Authorization (PA) Criteria 2017 Prior Authorization (PA) Certain drugs require prior authorization from EmblemHealth Medicare HMO/PPO Medicare Plans. This means that your doctor must contact us to get approval before prescribing

More information

Pegylated Interferon Agents for Hepatitis C

Pegylated Interferon Agents for Hepatitis C Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection

More information

Biologic Immunomodulators Prior Authorization and Quantity Limit Program Summary (Specialty Drug Management)

Biologic Immunomodulators Prior Authorization and Quantity Limit Program Summary (Specialty Drug Management) RA PSA AS PS UC CD PJIA SJIA HS UVEITIS CAPS/NOMID GIANT CELL ARTERITIS Horizon BCBSNJ Medical Necessity Guideline Biologic Immunomodulators Prior Authorization and Quantity Limit Program Summary (Specialty

More information

Psoriatic Arthritis- Second Line Treatments

Psoriatic Arthritis- Second Line Treatments Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist

More information

Drug Class Review Monograph GPI Class 12 Antivirals

Drug Class Review Monograph GPI Class 12 Antivirals Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,

More information

2012 Medicare National Preferred 4 Tier PA Criteria

2012 Medicare National Preferred 4 Tier PA Criteria 2012 Medicare National Preferred 4 Tier PA Criteria ACTEMRA... 14 ACTEMRA... 14 ALPHA-1 PROTEINASE INHIBITORS... 16 ARALAST NP... 16 GLASSIA... 16 PROLASTIN C... 16 PROLASTIN... 16 ZEMAIRA... 16 AMEVIVE...

More information

PRIOR AUTHORIZATION PROTOCOLS

PRIOR AUTHORIZATION PROTOCOLS PRIOR AUTHORIZATION PROTOCOLS How do I request an exception to the Central Health Plan s Formulary? You can ask Central Health Plan to make an exception to our coverage rules. There are several types of

More information

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your Akamai Advantage plan before filling prescriptions for the drugs shown in the chart below.

More information

P&T Committee Meeting Minutes (GHP Family Business) September 17, 2013

P&T Committee Meeting Minutes (GHP Family Business) September 17, 2013 P&T Committee Meeting Minutes (GHP Family Business) September 17, 2013 Present: Bret Yarczower, MD, MBA, Chair Ali Akram, Pharm.D. MBA Kristen Bender, Pharm.D. Keith Boell, DO Holly Bones, Pharm.D. - via

More information

Somavert ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D.

Somavert ALL FDA-APPROVED INDICATIONS NOT OTHERWISE EXCLUDED FROM PART D. ACROMEGALY THERAPY Somatuline Depot subcutaneous syringe 120 mg/0.5 ml, 60 mg/0.2 ml, 90 mg/0.3 ml Somavert Age Other ALL FDA-APPROVED INDICATIONS NOT OTHERWISE PATIENT PROGRESS NOTES, DOCUMENTATION OF

More information

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use 3 August 206 EMA/52958/206 Information Management Division Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use August 206 This document lists information

More information

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices

2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices 2018 PRIOR AUTHORIZATION CRITERIA UCare Choices Fairview UCare Choices UCare requires your physician to get prior authorization for certain drugs. This means that you will need to get approval from UCare

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

Pharmacy Clinical Prior Authorization Assistance Chart Effective February 2018

Pharmacy Clinical Prior Authorization Assistance Chart Effective February 2018 About Pharmacy Clinical Prior Authorizations Clinical prior authorizations (PA) are based on evidence-based clinical criteria and nationally recognized peer-reviewed information. The PA may apply to an

More information

Selecting HCV Treatment

Selecting HCV Treatment Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are

More information

Do you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No

Do you or did you have any family members who have been diagnosed with MS? Yes No I Don t Know. Yes identical Yes not identical No The following survey will ask you questions about your family history of MS, your MS diagnosis and history, your symptoms, and your treatments. You may find it easier to fully answer these questions if

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

Drug Class Monograph. Policy/Criteria:

Drug Class Monograph. Policy/Criteria: Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),

More information

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic

More information

New chemical Entity Registered ( )

New chemical Entity Registered ( ) N# Product Name Registration Date )ل ف ) 1 Dosage form Strength Active Ingredient Marketing Authorization Holder 1 pegus 25/5/2005 tab 200 Ribavarin Shawi Roche 2 Velcade 7/7/2005 vial 3.5 bortezomib mina

More information

Rituxan. Rituxan (rituximab) Description

Rituxan. Rituxan (rituximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.10 Subject: Rituxan Page: 1 of 9 Last Review Date: December 3, 2015 Rituxan Description Rituxan (rituximab)

More information

Alberta Human Services Drug Benefit Supplement

Alberta Human Services Drug Benefit Supplement Alberta Human Services Drug Benefit Supplement Effective April 1, 2012 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton, AB T5J 3C5 Telephone Number: (780)

More information

Self-Injected Medications and Disposal Recommendations

Self-Injected Medications and Disposal Recommendations Actimmune (interferon gamma 1b) Apokyn (apomorphine hydrochloride) Arixtra (fondaparinux) Avonex (interferon beta 1a) Betaseron (interferon beta 1b) Copaxone (glatiramer acetate) Edex (alprostadil) InterMune

More information

Humira (adalimumab) DRUG.00002

Humira (adalimumab) DRUG.00002 Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml

More information

Drug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules

Drug Bill As Unit Common Directions Common Day Supply Common Billing Errors Oral Tablets/Capsules Note: This is a guide for commonly misbilled medications. Please submit the claims according to directions for use indicated on the prescription order. Drug Bill As Unit Common Directions Common Day Supply

More information

For Rheumatoid Arthritis

For Rheumatoid Arthritis For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form

More information

All medically accepted Prior authorization applies to new starts only excluded from Part D. 12 months

All medically accepted Prior authorization applies to new starts only excluded from Part D. 12 months 2018 Cigna-HealthSpring Prior Authorization Criteria Drug Name Excluded Prior Authorization Product Age Prescriber Coverage Covered Uses Exclusion Criteria Required Medical Information Other Criteria Drug

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

Please call the Customer Service number on the back of your BCBSM ID card if you have questions about your drug coverage or a drug claim.

Please call the Customer Service number on the back of your BCBSM ID card if you have questions about your drug coverage or a drug claim. Medicare Plus Blue PPO Essential, Vitality, Signature and Assure Plus Comprehensive Formulary Prior Authorization / Step Therapy Program 2017 Plan Year (Updated ) BCBSM Medicare Plus Blue PPO Essential,

More information